×

Contracts License Agreements

  • PARIS, Nov 9- Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday. Under the terms of the deal, Principia will grant Sanofi an exclusive, worldwide license to develop and commercialise PRN2246, a drug...

  • PARIS, Nov 9- Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday. Under the terms of the deal, Principia will grant Sanofi an exclusive, worldwide license to develop and commercialize PRN2246, a drug...

  • Cramer Remix: How Under Armour could turn around

    Jim Cramer highlighted why Under Armour might be a buy after a tough day.

  • Jim Cramer on the set of Mad Money.

    Jim Cramer highlighted why Under Armour might be a buy after a tough day.

  • Shutterstock CEO: We're going to see a 'dramatic turn' to mobile in photos we sell

    Jim Cramer spoke to the CEO of Shutterstock, who spoke about his photo licensing company's prospects and forward-looking guidance.

  • The company's shares rose as much as 8 percent in light trading but pared gains to trade at $120 before the bell. "Any concerns surrounding the discontinuation of the program should, for the most part, be quelled by the simultaneous execution of a potentially lucrative licensing agreement," Leerink analyst Paul Matteis said. San Francisco, California based Vir...

  • The company's shares rose as much as 8 percent in light trading but pared gains to trade at $120 before the bell. "Any concerns surrounding the discontinuation of the program should, for the most part, be quelled by the simultaneous execution of a potentially lucrative licensing agreement," Leerink analyst Paul Matteis said. San Francisco, California based Vir...

  • Exelixis plans to file for an expanded label for the drug with the U.S. Food and Drug Administration in the first quarter of 2018.. Exelixis and France's Ipsen jointly announced a licensing agreement last year for the commercialization and further development of the drug outside the United States, Canada and Japan. Hepatocellular carcinoma liver cancer is...

  • Brand Licensing Europe: The $262BN business and why it's great for marketers

    From Peter Rabbit in the 1930s to massive global business worth billions. James Wright talks to Steven Ekstract about the value of licensing in marketing.

  • How a smile turned into a $265M business

    Did you know that the yellow smiley emoji or emoticon dates back to 1972 and is a huge moneyspinner? CNBC talks to Nicolas Loufrani, son of the creator.

  • Apple cuts off Qualcomm

    Henry Blodget, Business Insider, and Scott Galloway, NYU Stern School of Business, discuss the dispute between Apple and Qualcomm over licensing.

  • Pandora CFO: A new paradigm for music consumption

    Michael Herring, CFO at Pandora, discusses the music streaming company's outlook as well as how Pandora stacks up against competitors.